Koninklijke DSM (OTCMKTS:RDSMY) has been given an average recommendation of “Hold” by the six analysts that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company.
Several analysts have recently issued reports on RDSMY shares. Zacks Investment Research upgraded shares of Koninklijke DSM from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Sanford C. Bernstein lowered shares of Koninklijke DSM from a “market perform” rating to an “underperform” rating in a research report on Wednesday, November 27th. Finally, ValuEngine upgraded shares of Koninklijke DSM from a “strong sell” rating to a “sell” rating in a research report on Friday, November 1st.
Shares of OTCMKTS RDSMY traded down $0.69 during trading on Friday, hitting $31.46. The stock had a trading volume of 179,913 shares, compared to its average volume of 102,189. Koninklijke DSM has a 12 month low of $19.45 and a 12 month high of $32.57. The company has a market capitalization of $22.83 billion, a PE ratio of 18.19, a PEG ratio of 2.39 and a beta of 1.40. The firm has a fifty day moving average of $31.40 and a two-hundred day moving average of $30.66.
Koninklijke DSM N.V., a science-based company, engages in nutrition, health, and materials businesses in the Netherlands, North America, the United Kingdom, France, Germany, Switzerland, the Asia-Pacific, and internationally.. The company operates through Nutrition, Materials, and Innovation Center segments.
Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.